World News: 14:14 GMT Friday 12th July 2019. [Research and Markets via Globe Newswire via SPi World News]
Dublin, July 12, 2019 (GLOBE NEWSWIRE) -- The report has been added to offering.
The global botulinum toxin & HA dermal filler market is estimated to reach US$11.06 billion in 2023, growing at a CAGR of 7.52%, for the period spanning from 2018 to 2023.
The factors such as increasing urban population, growing ageing population, rising female workforce, escalating personal disposable income, evolving personal healthcare expenditure and the growing number of plastic surgery and dermatology clinics are expected to drive the market growth.
However, the growth of the industry would be challenged by stringent regulations, patient health-associated risk and limited access to patent rights.
A few notable trends include accelerating pharmaceutical R&D spending, progressing botulinum toxin products pipeline, rising minimally invasive procedures and growing preference for combination therapy.
Presently, botulinum toxin and HA dermal fillers are widely used in therapeutics and aesthetics procedures for various purposes. Demand for these products was higher in therapeutic sector due to increasing approval of these injectables to manage nerve and muscular spasticity disorders by medicinal authorities.
The fastest-growing regional market is North America owing to the increasing geriatric population and rising demand for non-invasive aesthetic procedures in the US and Canada. The US is the largest market of botulinum toxin and HA dermal fillers and is already well-penetrated at developed market levels.
Dermal filler (injectable cosmetic filler, injectable facial filler) is a soft tissue filler that is injected into the skin to fill wrinkles, restoring a smoother appearance. Most of the effect is temporary because they are eventually absorbed by the body. The result lasts for about six months or longer. Presently, HA Dermal fillers are the most popular product type used by plastic surgeons for filling wrinkles.
Hyaluronic Acid (HA) is a naturally occurring non-sulfated glycosaminoglycan polymer component of the extracellular matrix that consists of disaccharide units of glucuronic acid and N-acetyl-glucosamine. It is widely distributed throughout the connective tissue, epithelial and nervous tissues in human beings.
HA dermal fillers are widely used to replace and restore human tissue. However, unlike botulinum toxin which is directly used to restrict a particular muscle movement, these products are directly injected into the skin to fill wrinkles /dermal or folded points on the body part.
They are also used to bring water to the surface of the skin to give it a fresh and gloomy look. In aesthetics procedures, HA dermal fillers are used during facial rejuvenation and wrinkle filling treatment. Different types of techniques are threading injection, multiple punctures, and anterograde or push-ahead filler techniques.
Also, owing to the success of pharmaceutical research and development relating to the therapeutic use of HA dermal fillers, it is used for treating atrophic scars, HIV-associated facial lipoatrophy, melolabial & mental creases, cosmetic disfigurement of the earlobe, steroid atrophy and hand & foot rejuvenation.
For more information about this report visit
Research and Markets also offers services providing focused, comprehensive and tailored research.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Medical Devices, Central Nervous System Drugs , Dermatology
Globe Newswire: 14:14 GMT Friday 12th July 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.